Regulatory News has published 1 story about BigHat Biosciences on 25 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 25 September 2026.
This page is generated from Regulatory News’ editorial coverage of BigHat Biosciences. It is not an advertisement.
On the record
- Company
- BigHat Biosciences, Inc.
- Headquarters
- San Mateo, California
- Founded
- 2019, by Mark DePristo and Peyton Greenside
- Regulator
- U.S. Food and Drug Administration (BHB810 is in Phase 1/2 clinical testing; no clearance or approval yet)
- Latest milestone
- $75 million Series C financing
Each line is taken from the most recent story of ours that states it.
Our coverage
